论文部分内容阅读
目的为了解乙型肝炎病毒ＨＢＶＤＮＡ和血清标志物与肝癌的关系。方法对经影像及甲胎蛋白阳性诊断确诊的５８例肝癌患者，采用ＰＣＲ和ＥＬＩＳＡ技术，分别进行了ＨＢＶＤＮＡ和血清标志物检测。结果肝癌患者乙型肝炎标志物阳性为９４８２％，标志物ＨＢｓＡｇ、ＨＢｅＡｇ、抗－ＨＢｃ阳性组占２２４１％。ＨＢＶＤＮＡ检测８例全部阳性；ＨＢｓＡｇ、抗－ＨＢｅ阳性组占５５１７％，ＨＢＶＤＮＡ检测１５例，７例阳性，阳性率为４６６６％。其他各组均低于７０％。结论认为肝癌的发生与ＨＢＶ感染紧密相关，尽管肝癌发生后ＨＢＶ复制受到抑制，但在ＨＢｓＡｇ、ＨＢｅＡｇ同时存在情况下ＨＢＶ复制依然活跃，当抗－ＨＢｅ标志物阳性时，肝癌的发生率最高（５５１７％），这可能与ＨＢＶＣ区变异株存在有关。
Objective To understand the relationship between hepatitis B virus HBVDNA and serum markers and liver cancer. Methods Fifty-eight HCC patients diagnosed by imaging and alpha-fetoprotein positive were detected by PCR and ELISA. HBVDNA and serum markers were detected respectively. Results The positive rate of hepatitis B in hepatocellular carcinoma patients was 9482%. The markers HBsAg, HBeAg and anti-HBc positive group accounted for 2241%. HBsAg and HBeAg positive group accounted for 55.17%, HBVDNA detected 15 cases, 7 cases were positive, the positive rate was 46.66%. The other groups were less than 7 0%. Conclusions The occurrence of hepatocellular carcinoma is closely related to HBV infection. Although HBV replication is inhibited after occurrence of hepatocellular carcinoma, HBV replication is still active in the presence of HBsAg and HBeAg. The incidence of hepatocellular carcinoma is the highest when anti-HBe markers are positive (55 17%), which may be related to the presence of HBVC mutation.